Patrick A.  Weiss net worth and biography

Patrick Weiss Biography and Net Worth

Patrick is a diversified and well rounded executive and serial entrepreneur with a wide range of experience in building, integrating and managing businesses across diverse market segments. His detailed understanding of highly technical manufacturing work flows and products is complemented by a proven track record of successfully creating organizations, product lines, technologies and processes to maximize performance. Prior to Twist Bioscience, Patrick consulted for a wide range of life science companies both to build start-up organizations and execute turnarounds. Previously, he served as President and CEO of Operon Biotechnologies Inc., a global leader of DNA synthesis services, where he turned around the business from net loss to profitability in a short period of time. He restructured the business, eventually negotiating a successful merger with Eurofins SA. Prior to Operon, he founded Xeragon, an international provider of RNA synthesis and bioinformatics products (now QIAGEN). Patrick received his MSc in Organic Chemistry, Analytical Chemistry, Molecular Biology, Genetics and Economics from the Swiss Federal Institute of Technology. He is an author of several issued patents.

What is Patrick A. Weiss' net worth?

The estimated net worth of Patrick A. Weiss is at least $1.81 million as of July 21st, 2021. Mr. Weiss owns 52,844 shares of Twist Bioscience stock worth more than $1,813,078 as of March 29th. This net worth estimate does not reflect any other investments that Mr. Weiss may own. Learn More about Patrick A. Weiss' net worth.

How do I contact Patrick A. Weiss?

The corporate mailing address for Mr. Weiss and other Twist Bioscience executives is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. Twist Bioscience can also be reached via phone at (800) 719-0671 and via email at [email protected]. Learn More on Patrick A. Weiss' contact information.

Has Patrick A. Weiss been buying or selling shares of Twist Bioscience?

Patrick A. Weiss has not been actively trading shares of Twist Bioscience during the past quarter. Most recently, Patrick Weiss sold 3,918 shares of the business's stock in a transaction on Tuesday, December 21st. The shares were sold at an average price of $82.85, for a transaction totalling $324,606.30. Learn More on Patrick A. Weiss' trading history.

Who are Twist Bioscience's active insiders?

Twist Bioscience's insider roster includes William Banyai (Insider), Robert Chess (Director), Keith Crandell (Director), Mark Daniels (Insider), Patrick Finn (Insider), Paula Green (SVP), Jan Johannessen (Director), Emily Leproust (CEO), James Thorburn (CFO), and Patrick Weiss (COO). Learn More on Twist Bioscience's active insiders.

Are insiders buying or selling shares of Twist Bioscience?

In the last year, Twist Bioscience insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $132,000.00. In the last year, insiders at the sold shares 9 times. They sold a total of 8,301 shares worth more than $294,281.96. The most recent insider tranaction occured on March, 20th when insider Dennis Cho sold 230 shares worth more than $7,709.60. Insiders at Twist Bioscience own 3.9% of the company. Learn More about insider trades at Twist Bioscience.

Information on this page was last updated on 3/20/2024.

Patrick A. Weiss Insider Trading History at Twist Bioscience

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/21/2021Sell3,918$82.85$324,606.30View SEC Filing Icon  
12/14/2021Sell2,801$84.00$235,284.00View SEC Filing Icon  
11/24/2021Sell2,801$95.29$266,907.29View SEC Filing Icon  
10/13/2021Sell4,906$104.00$510,224.00View SEC Filing Icon  
7/21/2021Sell4,905$119.75$587,373.7552,844View SEC Filing Icon  
6/23/2021Sell4,905$118.34$580,457.7053,080View SEC Filing Icon  
5/19/2021Sell4,905$88.39$433,552.9554,308View SEC Filing Icon  
4/21/2021Sell4,906$124.42$610,404.5254,589View SEC Filing Icon  
3/24/2021Sell14,639$132.50$1,939,667.5061,756View SEC Filing Icon  
12/10/2020Sell3,550$138.62$492,101.0054,481View SEC Filing Icon  
11/13/2020Sell3,550$107.20$380,560.0055,709View SEC Filing Icon  
9/18/2020Sell14,671$61.83$907,107.9364,401View SEC Filing Icon  
2/6/2020Sell7,680$28.16$216,268.8085,950View SEC Filing Icon  
2/4/2020Sell4,090$26.21$107,198.9087,449View SEC Filing Icon  
1/21/2020Sell4,089$22.29$91,143.8195,628View SEC Filing Icon  
10/16/2019Sell14,728$24.14$355,533.92
10/2/2019Sell14,729$22.86$336,704.94
9/18/2019Sell14,728$29.78$438,599.84
9/4/2019Sell14,728$27.66$407,376.48108,969View SEC Filing Icon  
8/21/2019Sell14,730$30.66$451,621.80View SEC Filing Icon  
See Full Table

Patrick A. Weiss Buying and Selling Activity at Twist Bioscience

This chart shows Patrick Weiss's buying and selling at Twist Bioscience by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Twist Bioscience Company Overview

Twist Bioscience logo
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $34.31
Low: $34.00
High: $35.09

50 Day Range

MA: $36.47
Low: $32.28
High: $41.50

2 Week Range

Now: $34.31
Low: $11.46
High: $43.21

Volume

1,187,678 shs

Average Volume

714,026 shs

Market Capitalization

$1.98 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.64